Saturday 17 October 2026
Export AXSM’s income statement to Excel — free account
Axsome Therapeutics, Inc.
AXSM Healthcare Biotechnology
Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024. In the quarter to June 2026, revenue grew 45.5%, EPS fell 2.06%, free cash flow fell 2.98% and total debt rose 4.66%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
157.14
4.65
−2.87%
Follow AXSM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 5 | 5 | 5 |
+8 more TTM periods Free account |
| (245.10%) | (349.38%) | (252.11%) | (275.50%) | ||
| (27.35%) | (28.74%) | (29.11%) | (37.30%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(97.28%) | (109.12%) | (86.93%) | (111.61%) | |
Average Days of Receivables |
130.41 | 129.39 | 128.32 | 127.79 | |
Free Cash Flow per Share |
(1.39) | (1.39) | (1.89) | (2.03) | |
Free Cash Flow |
(71.96) | (70.99) | (93.88) | (101.39) | |
Capital Expenditures |
(0.70) | (0.26) | (0.48) | (0.44) | |
| Other line items | |||||
Cash ROIC |
(13.57%) | (14.69%) | (17.61%) | (19.45%) | |
Accounts Receivable Turnover |
3.26 | 3.43 | 3.48 | 3.50 | |
Accounts Payable Turnover |
0.62 | 0.55 | 0.69 | 0.77 | |
Inventory Turnover |
1.87 | 2.19 | 2.17 | 2.40 | |
Average Days of Payables |
548.71 | 743.05 | 503.83 | 433.46 | |
Days of Inventory on Hand |
263.23 | 219.46 | 214.78 | 190.03 | |
Tax Rate |
0.00 | 0.00 | (0.01) | 0.00 | |
Research and Development Expense of Revenue |
24.19% | 26.99% | 28.70% | 33.76% | |
Selling, General and Administrative Expense of Revenue |
91.77% | 89.63% | 89.37% | 91.68% | |
Share Based Compensation of Revenue |
12.42% | 13.26% | 14.68% | 16.57% | |
Interest Coverage |
(37.09) | (32.60) | (25.43) | (27.97) | |
Operating CF/Net income |
0.37 | 0.38 | 0.51 | 0.44 | |
Depreciation/Fixed assets |
12.11 | 17.80 | 18.45 | 17.71 | |
Capex/Depreciation |
(0.07) | (0.03) | (0.05) | (0.04) | |
Revenue per Share |
14.99 | 13.83 | 12.83 | 11.22 | |
Operating CF per Share |
(1.38) | (1.38) | (1.88) | (2.02) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates